Trial Profile
Predictive factors in Capecitabine plus CDDP therapy in patients with HER2 negative advanced gastric cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Feb 2019
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Cisplatin
- Indications Adenocarcinoma; Gastric cancer
- Focus Therapeutic Use
- 20 Feb 2019 Status changed from active, no longer recruiting to completed.
- 15 Feb 2019 Planned End Date changed from 31 Aug 2014 to 31 Aug 2015.
- 15 Feb 2019 Status has been changed to active, no longer recruiting.